Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans

Cephalalgia

Volumn 32, Issue 2, 2012, Pages 150-158

  Kellerman, D ^a   Kori, S ^a   Forst, A ^a   Chang, J ^a   Febbraro, S ^b   Wutann, L ^b   Thomas, T ^b   Taylor, G ^c   Dodick, D W ^d  

^a MAP Pharmaceuticals Inc   (United States)

^b SIMBEC RESEARCH LTD   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d MAYO CLINIC   (United States)

Author keywords

CYP3A4; drug interaction; inhaled dihydroergotamine; MAP0004; Migraine

Indexed keywords

CYTOCHROME P450 3A4; DIHYDROERGOTAMINE; KETOCONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; FLUSHING; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PHARMACOKINETICS; PRURITUS; SIDE EFFECT; SKIN IRRITATION; VOMITING;

14-ALPHA DEMETHYLASE INHIBITORS; ADMINISTRATION, INHALATION; ADULT; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP3A; DIHYDROERGOTAMINE; DRUG INTERACTIONS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIGRAINE DISORDERS; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84856193424     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102411432299     Document Type: Article

References (22)

1. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 ; 43: 144-166 (Pubitemid 36188447)
2. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008 ; 28: 877-886
3. Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982 ; 13: 785-790 (Pubitemid 13139859)
4. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984 ; 26: 463-470 (Pubitemid 14149126)
5. Delaforge M, Rivière R, Sartori E, Doignon JL, Grognet JM. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica. 1989 ; 19: 1285-1295 (Pubitemid 19275642)
6. Martinet M, Kiechel JR. Interaction of dihydroergotamine and triacetyloleandomycin in the minipig. Eur J Drug Metab Pharmacokinet. 1983 ; 8: 261-267 (Pubitemid 14230587)
7. Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Fundam Clin Pharmacol. 1991 ; 5: 47-52
8. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med. 1988 ; 109: 249-249
9. Franco A, Bourlard P, Massot C, Lecoeur J, Guidicelli H, Bessard G. Acute ergotism caused by dihydroergotamine-triacetyloleandomycin association [Article in French]. Nouv Presse Med. 1978 ; 7: 205-205
10. D.H.E. 45 (dihydroergotamine mesylate) injection (package insert). Valeant Pharmaceuticals, Aliso Viejo, CA, 2009.
11. Migranal® (dihydroergotamine mesylate) nasal spray (package insert). Valeant Pharmaceuticals, Aliso Viejo, CA, 2007.
12. Cook RO, Shrewsbury SB, Okikawa J, et al. Delivery performance of dihydroergotamine mesylate (DHE) using the breath synchronized, plume controlled TEMPO™ inhaler (BSPCI). Respir Drug Deliv. 2006 ; 3: 687-690
13. Berenberg E, Clemons D, Kellerman D, Kori S, Noveck RJ. A randomized, double-blind, placebo controlled, three-period crossover study comparing the acute effects of LEVADEX® (MAP0004, orally inhaled DHE) and intravenous DHE on pulmonary arterial systolic pressure. Headache. 2011 ; 51: 1-66
14. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009 ; 49: 1423-1434
15. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan N. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) inhaler. Headache. 2007 ; 48: 355-367
16. Kellerman D, Kori S, Forst A, et al. The major metabolite of dihydroergotamine (DHE) after oral inhalation and IV administration does not significantly contribute to the pharmacologic activity. Presented at the 63rd Annual Meeting of the American Association of Neurology, April 2011.
17. Pichard L, Fabre I, Fabre G, et al. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos. 1990 ; 18: 595-606 (Pubitemid 20348846)
18. FDA Center for Drug Evaluation and Research (CDER). Guidance for industry: in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. November 1999.
19. Atiee G, Lasseter K, Baughman S, et al. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. J Clin Pharmacol. Epub ahead of print 29 September 2011.
20. Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN2897, a potent C-C chemokine receptor-1 antagonist. J Pharmacol Exp Ther. 2010 ; 332: 562-568
21. Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997 ; 37 (Suppl 1). S33 - S41
22. Shrewsbury SB, Kori SH, Miller SD, Pedinoff A, Weinstein S. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008 ; 24: 1977-1985